Want to see TLRY full AI Analyst Report?
TLRY Stock Chart & Stats
$6.86
-$0.07(-5.17%)
At close: 4:00 PM EST
$6.86
-$0.07(-5.17%)
Day’s Range― - ―
52-Week Range$4.20 - $23.20
Previous CloseN/A
Volume22.72M
Average Volume (3M)3.59M
Market Cap
$530.41M
Enterprise Value$680.58M
Total Cash (Recent Filing)$219.93M
Total Debt (Recent Filing)$317.08M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Jul 29, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-18.70
Shares Outstanding120,002,890
10 Day Avg. Volume3,546,736
30 Day Avg. Volume3,587,971
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.18
Price to Sales (P/S)0.34
P/FCF Ratio-2.17
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue0.58
Enterprise Value/Gross Profit2.08
Enterprise Value/Ebitda-0.37
Forecast
1Y Price Target
$6.50Price Target Upside-5.25% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.38
Revenue Forecast (FY)$1.09B
Bulls Say, Bears Say
Bulls Say
Revenue & EBITDA MomentumA record quarter of revenue coupled with reiterated adjusted EBITDA guidance signals operational progress and scalable economics. Over 2–6 months this supports improved cash generation potential, validates cost actions, and gives management room to prioritize growth or deleveraging without relying solely on emergency financing.
Distribution & International GrowthMaterial distribution expansion and rapid international cannabis volume growth create durable route-to-market advantages. Expanded pharmacy reach and third-party partnerships deepen market access, diversify revenue streams, and raise barriers to entry versus smaller competitors over the medium term.
Balance Sheet & Debt ReductionActive debt-for-equity swaps and improved cash balances reduce near-term interest and maturity pressure, improving financial flexibility. Lower convertible debt and a stronger liquidity cushion make the company more resilient to sector volatility and better positioned to fund integrations or strategic investments.
Bears Say
Persistent Losses & Cash BurnLarge trailing net losses and negative operating/free cash flow indicate the business is not yet self-funding. Continued cash burn forces reliance on equity or debt markets, risks further equity dilution or balance-sheet strain, and constrains reinvestment in brands, production, and international expansion over the medium term.
Beverage Segment Pressure & Integration RiskThe beverage platform faces near-term volume and margin headwinds while integration of recent acquisitions requires stabilization. Given the business’s material revenue contribution pro forma, persistent margin pressure or execution missteps could meaningfully weigh on consolidated cash flow and delay expected beverage profitability.
Regulatory Uncertainty In U.S. Hemp/CannabisUnresolved U.S. regulatory risk could structurally shrink addressable markets for hemp-derived THC beverages and require reformulation, relabeling, or withdrawal of SKUs. Regulatory shifts would raise compliance costs, reduce future revenue visibility, and complicate capital allocation for U.S. growth plans across a multi-month horizon.
Tilray News
TLRY FAQ
What was Tilray’s price range in the past 12 months?
Tilray lowest stock price was $4.20 and its highest was $23.20 in the past 12 months.
What is Tilray’s market cap?
Tilray’s market cap is $530.41M.
When is Tilray’s upcoming earnings report date?
Tilray’s upcoming earnings report date is Jul 29, 2026 which is in 16 days.
How were Tilray’s earnings last quarter?
Tilray released its earnings results on Apr 01, 2026. The company reported -$0.224 earnings per share for the quarter, missing the consensus estimate of -$0.136 by -$0.088.
Is Tilray overvalued?
According to Wall Street analysts Tilray’s price is currently Overvalued.
Does Tilray pay dividends?
Tilray does not currently pay dividends.
What is Tilray’s EPS estimate?
Tilray’s EPS estimate is >-0.01.
How many shares outstanding does Tilray have?
Tilray has 120,002,890 shares outstanding.
What happened to Tilray’s price movement after its last earnings report?
Tilray reported an EPS of -$0.224 in its last earnings report, missing expectations of -$0.136. Following the earnings report the stock price went down -5.1%.
Which hedge fund is a major shareholder of Tilray?
Currently, no hedge funds are holding shares in TLRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tilray Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.50 (-5.25% Downside)
$6.50 (-5.25% Downside)
Blogger Sentiment
Neutral
TLRY Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 359.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $232.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 15.6%
Last 30 Days ▲ 8.5%
Last 30 Days ▲ 8.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.62%
12-Months-Change
Fundamentals
Return on Equity
-92.82%
Trailing 12-Months
Asset Growth
-39.04%
Trailing 12-Months
Company Description
Tilray
Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray's portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.
TLRY Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted clear operational progress: record quarterly revenue, strong international cannabis momentum, meaningful distribution growth, completed cost-savings programs and strategic beverage partnerships/acquisition that materially expand the company’s scale. Several significant challenges remain — beverage revenue and margin pressure, input cost volatility (aluminum, fuel), working capital-related cash use, regulatory uncertainty in the U.S., and integration work for BrewDog — but management presented concrete actions (hedging, Project 420, SKU rationalization, partnerships) and a strengthened liquidity position. On balance, the positive operational and strategic developments outweigh the near-term headwinds.View all TLRY earnings summariesTLRY Stock 12 Month Forecast
Average Price Target
$6.50
▼(-5.25% Downside)
Technical Analysis
Ownership Overview
6.76% Insiders
0.41% Mutual Funds
<0.01% Other Institutional Investors
89.46% Public Companies and Individual Investors












